Table of Content - U.S. Urea Cycle Disorders Treatment Market

Urea cycle disorders are congenital diseases that are caused by a dysfunctional urea cycle. Urea cycle disorders are the result of a deficiency of one of the six enzymes that catalyze the various biochemical reactions in the urea cycle which converts ammonia to urea for removal via urine. Urea cycle disorders belong to inborn errors of metabolism that are associated with fatal brain damage and death in newborns. The diagnosis of urea cycle disorder is done by the analysis of urine and blood for abnormal metabolites such as substances produced by metabolism and high ammonia levels. Frequent blood tests are done to monitor ammonia levels. The treatment of urea cycle disorders consists of dietary management to limit ammonia production. A liver transplant can be an effective treatment for urea cycle disorder for the proper functioning of the urea cycle

Market Dynamics

Increasing product approvals by regulatory bodies which is expected to drive the market growth over the forecast period. For instance, In October 2020, Aeglea Biotherapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to ACN00177 for the treatment of Homocystinuria, a serious metabolic disorder characterized by elevated plasma homocysteine, which leads to a wide range of life-altering complications and reduced life expectancy.

Increasing product launches by key players for ornithine transcarbamylase (OTC) deficiency treatment is expected to drive market growth over the forecast period. For instance, in September 2022, Medunik USA, a pharmaceutical company, announced the launch of Pheburane oral pellets, a unique taste-masked formulation of sodium phenylbutyrate (NaPB). Pheburane is a prescription medicine, used along with a specific diet, for the long-term management of adults and children with urea cycle disorders (UCDs).

Key features of the study:

This report provides in-depth analysis of the U.S. urea cycle disorders market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the U.S. urea cycle disorders market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies Key companies covered as a part of this study include Horizon Therapeutics Plc, Bausch Health Companies Inc, Recordati Rare Diseases Inc., Nestlé S.A., Danone S.A., Lucane Pharma SA, Acer Therapeutics Inc., Ultragenyx Pharmaceutical Inc., Aeglea Biotherapeutics, Inc., Arcturus Therapeutics Holdings Inc., Orpharma Pty Ltd., Selecta Biosciences, Inc., Abbott, and Mead Johnson & Company, LLC
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The U.S. urea cycle disorders market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the U.S. urea cycle disorders market

Detailed Segmentation:

U.S. Urea Cycle Disorders Treatment Market, By Treatment Type:
- Amino Acid Supplements
- Sodium Phenylbutyrate
- Glycerol Phenylbutyrate
- Sodium Benzoate
- Others
U.S. Urea Cycle Disorders Treatment Market, By Enzyme Deficiency Type :
- OTC – Ornithine Transcarbamylase
- AS – Argininosuccinate Synthetase (citrullinemia)
- AG – Arginase
- AL – Argininosuccinate Lyase
- CPS1 – Carbamoyl Phosphate Synthase
- NAGS – N-acetylglutamate Synthase
U.S. Urea Cycle Disorders Treatment Market, By Route of Administration:
- Oral
- Injectable
U.S. Urea Cycle Disorders Treatment Market, By Distribution channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Company Profiles
- Horizon Therapeutics Plc.*
  - Company Highlights
  - Products Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Bausch Health Companies Inc.
- Recordati Rare Diseases Inc.
- Nestlé S.A.
- Danone S.A.
- Lucane Pharma SA
- Acer Therapeutics Inc.
- Ultragenyx Pharmaceutical
- Aeglea Biotherapeutics, Inc
- Arcturus Therapeutics Holdings Inc.
- Orpharma Pty Ltd.
- Selecta Biosciences, Inc.
- Abbott
- Mead Johnson & Company, LLC

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
Market Purview
- Report Description
  - Market Definition and Scope
- Executive Summary
  - Market Snapshot, By Treatment Type
  - Market Snapshot, By Enzyme Deficiency Type
  - Market Snapshot, By Route of Administration
  - Market Snapshot, By Distribution Channel
- Coherent Opportunity Map (COM)
Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
  - Drivers
  - Restraints
  - Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Treatment Landscape
- Strategic Partnership And Agreement
- Pipeline Analysis
- Regulatory Scenario
- Reimbursement Scenario
- PEST Analysis
- Epidemiology
- Therapeutics Overview
- Product/Brand Analysis
- Urea Cycle Disorder (UCD) Treatment Competitive Overview
- Urea Cycle Disorder (UCD) Patient Journey
U.S. Urea Cycle Disorders Treatment Market– Impact of Coronavirus (COVID-19) Pandemic
- Economic Impact
- Impact on Supply Side and Demand
U.S. Urea Cycle Disorders Treatment Market, By Treatment Type, 2020–2032, (US$ Mn)
- Introduction
  - Market Share Analysis, 2025 and 2032 (%)
  - Y-o-Y Growth Analysis, 2021 – 2032
  - Segment Trends
- Amino Acid Supplements
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020–2032,(US$ Mn)
- Sodium Phenylbutyrate
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020–2032,(US$ Mn)
- Glycerol Phenylbutyrate
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020–2032,(US$ Mn)
- Sodium Benzoate
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020–2032,(US$ Mn)
- Others
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020–2032,(US$ Mn)
S. Urea Cycle Disorders Treatment Market, By Enzyme Deficiency Type, 2020–2032, (US$ Mn)
- Introduction
  - Market Share Analysis, 2025 and 2032 (%)
  - Y-o-Y Growth Analysis, 2021 – 2032
  - Segment Trends
- OTC – Ornithine Transcarbamylase
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020–2032,(US$ Mn)
- AS – Argininosuccinate Synthetase (citrullinemia)
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020–2032,(US$ Mn)
- AG – Arginase
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020–2032,(US$ Mn)
- AL – Argininosuccinate Lyase
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020–2032,(US$ Mn)
- CPS1 – Carbamoyl Phosphate Synthase
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020–2032,(US$ Mn)
- NAGS – N-acetylglutamate Synthase
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020–2032,(US$ Mn)
U.S. Urea Cycle Disorders Treatment Market, By Route of Administration, 2020–2032, (US$ Mn)
- Introduction
  - Market Share Analysis, 2025 and 2032 (%)
  - Y-o-Y Growth Analysis, 2021 – 2032
  - Segment Trends
- Oral
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020–2032,(US$ Mn)
- Injectable
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020–2032,(US$ Mn)
U.S. Urea Cycle Disorders Treatment Market, By Distribution Channel, 2020–2032, (US$ Mn)
- Introduction
  - Market Share Analysis, 2025 and 2032 (%)
  - Y-o-Y Growth Analysis, 2021 – 2032
  - Segment Trends
- Hospital Pharmacies
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020–2032,(US$ Mn)
- Retail Pharmacies
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020–2032,(US$ Mn)
- Online Pharmacies
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020–2032,(US$ Mn)
Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
  - Horizon Therapeutics Plc.
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Strategies
  - Bausch Health Companies Inc.
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Strategies
  - Recordati Rare Diseases Inc.
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Strategies
  - Nestlé S.A.
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Strategies
  - Danone S.A.
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Strategies
  - Lucane Pharma SA
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Strategies
  - Acer Therapeutics Inc.
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Strategies
  - Ultragenyx Pharmaceutical Inc.
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Strategies
  - Aeglea Biotherapeutics, Inc.
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Strategies
  - Arcturus Therapeutics Holdings Inc.
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Strategies
  - Orpharma Pty Ltd.
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Strategies
  - Selecta Biosciences, Inc.
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Strategies
  - Abbott
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Strategies
  - Mead Johnson & Company, LLC
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Strategies
Section
- Research Methodology
- About us

*Browse 13 market data tables and 24 figures on "U.S. Urea Cycle Disorders Treatment Market” - Forecast to 2032

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now

Credibility and Certifications

860519526

9001:2015

27001:2022

Need a Custom Report?

EXISTING CLIENTELE